Fondazione Italiana Linfomi - Ets

This study is for people with follicular lymphoma that has returned or stopped responding to initial treatment. It tests whether adding a drug called lenalidomide to standard rituximab maintenance therapy can keep the cancer in remission longer and with manageable side effects. T…

This large, late-stage trial is testing if a shorter course of chemotherapy works as well as the standard, longer treatment for controlling advanced follicular lymphoma when combined with immunotherapy. The study involves over 600 adults with newly diagnosed, high-burden disease.…

This study is testing whether adding the drug ibrutinib to standard chemotherapy (R-CHOP) helps control a fast-growing type of lymphoma. It is for 75 adults under 65 who have this specific type and are at high risk of the cancer returning. The goal is to see if this combination k…

This study is testing if adding a drug called Romidepsin to standard chemotherapy (CHOEP) makes treatment more effective for young adults with aggressive types of T-cell lymphoma. The goal is to better control the cancer before patients receive a stem cell transplant. The trial f…

This study is observing how well the drug zanubrutinib works and what side effects patients experience in real-world medical practice in Italy. It includes 212 adults with Waldenström's Macroglobulinemia, a rare blood cancer, who were treated through a special access program or a…

This study aims to understand why mantle cell lymphoma, a type of blood cancer, sometimes returns or resists standard treatments. Researchers will analyze stored tissue samples from 160 patients whose cancer came back after initial therapy. By studying the cancer cells in detail,…

This study looks back at medical records from 241 patients who developed a type of cancer called PTLD after an organ or stem cell transplant. The goal is to understand which patients do better or worse, what treatments were used, and how effective they were. This information will…